Society
Society
Appointment

UCL appoints Director of Research at UCLH and Director of the NIHR UCLH Biomedical Research Centre

Professor Karl Peggs takes up Director roles leading clinical research partnership with University College London Hospitals NHS Foundation Trust

UCL Professor Karl Peggs has been appointed Director of Research at University College London Hospitals NHS Foundation Trust (UCLH) and Director of the National Institute for Health and Care Research (NIHR) UCLH Biomedical Research Centre (BRC).

UCLH is one of the UK’s leading hospitals for both patient care and research and is one of only two UK hospitals ranked in the world’s top 60.  The NIHR UCLH Biomedical Research Centre (BRC) is a partnership between UCLH and UCL, a top 10 world leading University (QS World Rankings 2024). By working together, they have become leaders in translating fundamental biomedical research into clinical research that benefits patients. They are dedicated to the diagnosis and treatment of many complex illnesses. UCLH specialises in women’s health and the treatment of cancer, infection, neurological, gastrointestinal and oral disease. It has world class support services including critical care, imaging, nuclear medicine and pathology.

The new Director of the NIHR UCLH BRC and Director of Research for UCLH will provide strategic leadership for clinical research, work closely with their key university partner, UCL  to deepen relationships with other academic, research, and industry partners. This position is instrumental in supporting UCLH to become a world leading research hospital.

Society undertook the task of identifying the highest calibre of individuals for this prestigious post. We pinpointed highly respected, academically credible clinician scientists, who are an inclusive leader with the ability to influence at all levels to act as a critical link between the pioneering medicine being practiced at UCLH and the innovative research of UCL scientists. We paid special attention to individuals with links to the NIHR, and the NHS.

Professor Karl Peggs is a Professor of Transplant Science and Cancer Immunotherapy at the UCL Cancer Institute, as well as a consultant in haematology and transplantation at UCLH, and Clinical and Scientific Director of UCLH’s Sir Naim Dangoor Centre for Cellular Immunotherapy. As co-founder and Chief Medical Officer of UCL spin-out company Achilles Therapeutics, Professor Peggs develops novel cancer immunotherapy treatments. The appointments follow a distinguished career in academia and medicine, with specialisms in viral infections, immune reconstitution, adoptive cellular therapies, and regulatory checkpoint-directed immune-therapeutics, spanning over 30 years.

Professor Peggs will take up the roles in August 2024. Society wishes him all the very best in his new role.

Related Articles